{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+ART&page=2", "query": { "intervention": "Oral ART", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+ART&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T01:33:38.483Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00344487", "title": "Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Lopinavir/Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2005-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00344487" }, { "nct_id": "NCT05729568", "title": "A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "Antiretroviral Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 83, "start_date": "2023-05-15", "completion_date": "2030-12", "has_results": true, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 29, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05729568" }, { "nct_id": "NCT02519777", "title": "Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Placebo for maraviroc (MVC)", "type": "DRUG" }, { "name": "Placebo for dolutegravir (DTG)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Maraviroc (MVC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2016-04-21", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2022-04-22", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 23, "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519777" }, { "nct_id": "NCT00125983", "title": "Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Pregnancy" ], "interventions": [ { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ortho Novum 1/35", "type": "DRUG" }, { "name": "Ortho Evra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "FEMALE", "summary": "13 Years and older · Female only" }, "enrollment_count": 32, "start_date": null, "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00125983" }, { "nct_id": "NCT00661960", "title": "Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "AIDS" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2008-03", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661960" }, { "nct_id": "NCT04039217", "title": "Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ART", "HIV" ], "interventions": [ { "name": "Biktarvy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 20, "start_date": "2019-09-30", "completion_date": "2020-08-28", "has_results": true, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039217" }, { "nct_id": "NCT01466595", "title": "Rifaximin as a Modulator of Microbial Translocation and Immune Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 73, "start_date": "2011-09", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466595" }, { "nct_id": "NCT04272242", "title": "Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "LTBI" ], "interventions": [ { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Antiretroviral Therapy (ART)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2021-02-27", "completion_date": "2021-12-27", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 2, "location_summary": "San Francisco, California • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04272242" }, { "nct_id": "NCT00000867", "title": "A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AIDS Dementia Complex", "HIV Infections" ], "interventions": [ { "name": "Memantine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "1996-12", "completion_date": "2001-07", "has_results": false, "last_update_posted_date": "2013-06-10", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 19, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000867" }, { "nct_id": "NCT02531295", "title": "Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Euphorbia kansui extract powder prepared as tea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-05-15", "completion_date": "2020-03-19", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-09-18T01:33:38.483Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531295" } ] }